VivoSim Labs, Inc. Insider Trading

VIVS

⊜ Compare

Last 12 months

Insiders bought 3K and sold 7K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

−5K

1 buy · 1 sale

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 1

executives and directors

Last open-market buy

Aug 2026

Aug 31, 2026

Get an email when VIVS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 31	Tony Serge Lialin Chief Commercial Officer	Bought	10,000	$0.28	3K	New	Form 4
Nov 17, 2025	David Gobel Director	SoldNo plan	3,266	$2.24	7K	New	Form 4

Aug 31
Tony Serge Lialin
Chief Commercial Officer · bought 10,000 at $0.28
3K
New position
Nov 17, 2025No plan
David Gobel
Director · sold 3,266 at $2.24
7K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VIVS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with VIVS

CompareIntrinsic value

AIMAIM ImmunoTech Inc.

$0.16+0.63%15

INMBInmune Bio Inc.

$1.33+0.76%10

ATYRAtyr Pharma Inc.

$6.18-6.79%10

SNTISenti Biosciences Inc.

$0.18-0.79%0

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

PALIPalisade Bio Inc.

$1.25+1.63%20

CRDFCardiff Oncology Inc.

$0.87+1.03%36

IMAImageneBio, Inc.

$4.10+1.99%10

Spot a number that looks wrong? Check it in VIVS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VIVS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.